# US Platelet Aggregation Devices Market

> US Platelet Aggregation Devices Market Research Report: Size, Share, Trend Analysis By Types (Optical Aggregation Devices, Electrochemical Aggregation Devices, Whole Blood Aggregation Devices), By Applications (Cardiology, Oncology, Neurology, Vascular Disorders), By End Users (Hospitals, Diagnostic Laboratories, Research Institutions) and By Modality (Point of Care Testing, Laboratory Testing) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 4.65%
- **2024:** $ 178.9 Million
- **2025:** $ 187.22 Million
- **2035:** $ 294.99 Million
- **Key Players:** Roche Diagnostics (CH), Siemens Healthineers (DE), Abbott Laboratories (US), Thermo Fisher Scientific (US), Beckman Coulter (US), Sysmex Corporation (JP), Acelity (US), Grifols (ES), HemoSonics (US)

**Report ID:** MRFR/HC/16100-HCR · **Pages:** 100 · **Author:** Rahul Gotadki & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-platelet-aggregation-devices-market-17628

---

## Market Summary

## **US Platelet Aggregation Devices Market Overview**

As per MRFR analysis, the US Platelet Aggregation Devices Market Size was estimated at 492.8 (USD Million) in 2023. The US Platelet Aggregation Devices Market Industry is expected to grow from 520.8 (USD Million) in 2024 to 980 (USD Million) by 2035. The US Platelet Aggregation Devices Market CAGR (growth rate) is expected to be around 5.916% during the forecast period (2025 - 2035).

### **Key US Platelet Aggregation Devices Market Trends Highlighted**

In the US Platelet Aggregation Devices Market, key market drivers include the increasing prevalence of cardiovascular diseases and the rising demand for minimally invasive diagnostic procedures. As heart-related conditions continue to be a leading cause of morbidity and mortality in the United States, there is a heightened focus on early diagnosis and monitoring of platelet function. This demand is further supported by technological advancements in medical devices that enhance the accuracy and efficiency of platelet aggregation tests.

Opportunities to be explored include the expansion of personalized medicine initiatives, as healthcare providers seek to tailor treatment plans based on individual patient profiles. This trend emphasizes the relevance of platelet aggregation tests in determining the appropriate therapeutic interventions for patients with specific coagulation disorders.

In recent times, there has been a shift towards point-of-care testing in the US, allowing for immediate results and quicker decision-making in critical care settings. This trend is particularly beneficial in emergency departments and outpatient clinics, where timely interventions can significantly impact patient outcomes. Additionally, the integration of digital health technologies and telemedicine has opened new avenues for patient monitoring and data management, facilitating better disease management.

Regulatory support from organizations like the FDA also encourages innovation in the platelet aggregation device market, fostering research and development in this area. As these trends evolve, the US Platelet Aggregation Devices Market is positioned for further growth, driven by healthcare professionals' and patients' increasing needs for reliable and rapid diagnostic tools.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Platelet Aggregation Devices Market Drivers**

### **Increasing Prevalence of Cardiovascular Diseases**

The rising incidence of cardiovascular diseases in the United States is significantly driving the US Platelet Aggregation Devices Market Industry. According to data from the American Heart Association, about 17.9 million people die from cardiovascular diseases every year, which is a leading cause of mortality. The National Heart, Lung, and Blood Institute reported that an estimated 30.3 million adults in the US have high blood pressure, a key risk factor for these diseases. This increasing rate of patients necessitates advanced diagnostic and therapeutic solutions, including platelet aggregation devices, which are crucial for assessing platelet function and managing cardiovascular health.

As established organizations like Abbott Laboratories and Siemens Healthineers continue to innovate and improve these devices, the market is expected to flourish in response to this growing demand.

### **Advancements in Diagnostic Technologies**

The technological advancements in diagnostic instruments play a pivotal role in the growth of the US Platelet Aggregation Devices Market Industry. The development of point-of-care testing devices that provide real-time results is gaining popularity among healthcare providers. An increasing number of hospitals in the United States are adopting automated systems for rapid testing, according to the Centers for Medicare & Medicaid Services, enhancing the accuracy of platelet aggregation tests.

Companies like AccuNET and PLAC Testing are at the forefront in introducing innovative solutions that bolster the capabilities of platelet aggregation devices, which further drives market expansion due to their enhanced reliability and efficiency.

### **Growing Research and Development Initiatives**

The surge in Research and Development initiatives for new platelet aggregation technologies is a significant driver for the US Platelet Aggregation Devices Market Industry. The National Institutes of Health has reported a 5% annual increase in funding for cardiovascular research, amounting to over 3 billion USD annually, aimed at improving vascular health and developing better diagnostic tools. This investment is fostering innovation and supporting emerging startups and established firms to create efficient and accurate devices, thus contributing to the overall growth of the market.

Institutions such as Boston Scientific and Thermo Fisher Scientific are leading the charge in pushing these advancements through their sustained R&D efforts.

## **US Platelet Aggregation Devices Market Segment Insights**

### **Platelet Aggregation Devices Market Type Insights**

The US **[Platelet Aggregation Devices Market](../../../reports/platelet-aggregation-devices-market-7450)** is notably segmented into various types, which play a crucial role in diagnosing and monitoring platelet function in clinical settings. Optical Aggregation Devices are essential for visualizing platelet aggregation by measuring light transmission through a sample, significantly aiding in real-time analysis. These devices are utilized widely in research and clinical labs due to their effectiveness and reliability, making them a preferred choice among healthcare professionals.

Electrochemical Aggregation Devices leverage the principles of electrochemistry to analyze platelet behavior, providing a unique advantage by offering rapid results and minimal sample volumes. These devices have gained popularity due to their compatibility with point-of-care testing, thus improving patient management in cardiovascular care.

Meanwhile, Whole Blood Aggregation Devices deliver a comprehensive assessment of platelet function using whole blood samples, which is vital for understanding a patient’s hemostatic profile in a more physiologically relevant manner. The increasing prevalence of cardiovascular diseases and an aging population in the US are key factors driving the demand for these diverse platelet aggregation solutions. Each type holds significant importance due to its distinct advantages in various clinical applications. The advancements and innovations in these technologies are expected to enhance their efficiency, encouraging higher adoption rates across healthcare facilities.

Overall, the segmentation by type within the US Platelet Aggregation Devices Market illustrates both the diversity in applications and the growing need for effective diagnostic and monitoring tools in hematology and cardiology. The continuous exploration of new materials, along with research and development initiatives focused on improving accuracy and usability, points towards a positive outlook for these device types in an evolving healthcare landscape.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Platelet Aggregation Devices Market Application Insights**

The US Platelet Aggregation Devices Market focused on the Application segment plays a crucial role in the healthcare landscape, particularly within the realms of Cardiology, Oncology, Neurology, and Vascular Disorders. This market facet is essential as it directly relates to patient care and the efficacy of treatments for various conditions that involve platelet activity.

Cardiology holds significant importance, given the prevalence of cardiovascular diseases, where platelet aggregation plays a pivotal role in heart attacks and strokes. Oncology benefits from these devices as they assist in monitoring platelet function, which is critical during cancer treatments that involve anticoagulants.

In Neurology, the monitoring of platelet aggregation is crucial for managing conditions such as stroke and dementia, highlighting its relevance in neurovascular health. Vascular Disorders considerably impact the market as these conditions require precise monitoring and intervention to prevent severe health events. The growing incidence of these health issues in the United States, compounded by an aging population, drives demand for advanced platelet aggregation devices tailored to these specific applications, ensuring continuous market growth and innovation within the industry.

The ability to provide accurate diagnostics and improve patient outcomes remains a focal point, propelling advancements in device technology and expanding the overall US Platelet Aggregation Devices Market.

### **Platelet Aggregation Devices Market End User Insights**

The US Platelet Aggregation Devices Market encompasses a variety of end users, prominently featuring hospitals, diagnostic laboratories, and research institutions, each playing a crucial role. Hospitals are key players in this market, utilizing platelet aggregation devices for crucial diagnostic and therapeutic purposes, particularly in cardiology and hematology, which underlines their importance in patient care.

Diagnostic laboratories significantly influence the market as they provide advanced testing services that enhance disease detection and monitoring, supporting hospitals with critical data. Research institutions also contribute by utilizing these devices for studies aimed at understanding platelets in disease processes, thereby driving innovation and development.

The growing prevalence of cardiovascular diseases and the increasing awareness about platelet-related disorders are expected to boost the demand across these end users. The US Platelet Aggregation Devices Market segmentation reflects a strong focus on these areas, driven by advancements in technology and a push towards personalized medicine.

### **Platelet Aggregation Devices Market Modality Insights**

The US Platelet Aggregation Devices Market, encompassing the Modality segment, is characterized by diverse approaches to testing, including Point of Care Testing and Laboratory Testing. Point of Care Testing has gained traction due to its rapid results, facilitating immediate clinical decisions and improving patient outcomes, particularly in emergency and critical care settings. This segment is essential for healthcare providers, enabling real-time monitoring of platelet function, which is crucial for managing various cardiovascular conditions.

On the other hand, Laboratory Testing remains a cornerstone of diagnosis, offering comprehensive and accurate assessments of platelet aggregation. This approach is favored in research and clinical laboratories for its detailed analysis. The increasing prevalence of cardiovascular diseases and the need for effective monitoring and treatment strategies are driving growth within both modalities. Furthermore, advancements in technology are enhancing the capabilities and accuracy of these devices, creating significant opportunities for market expansion.

As healthcare systems emphasize personalized medicine, the importance of both Point of Care and Laboratory Testing in the US Platelet Aggregation Devices Market becomes increasingly relevant, positioning them as vital components in contemporary healthcare.

## **US Platelet Aggregation Devices Market Key Players and Competitive Insights**

The US Platelet Aggregation Devices Market is characterized by a growing demand driven by an increasing prevalence of cardiovascular diseases and the rising awareness regarding the importance of early diagnosis and management of hemostatic disorders. Companies in this space are focused on innovation, striving to enhance the accuracy and efficiency of platelet aggregation testing processes. The competitive landscape is defined by various players who are investing significantly in research and development to bring forth innovative products that comply with regulatory standards and meet clinical needs.

This dynamic sector is under constant evolution, with a notable push towards integrating advanced technologies such as automated systems and digital solutions to improve patient outcomes and streamline processes within clinical settings. Additionally, staying abreast of regulatory requirements and forming strategic alliances play crucial roles in gaining a competitive edge within this fast-paced market.

BioRad Laboratories holds a significant position within the US Platelet Aggregation Devices Market, leveraging advanced technology and expertise in blood diagnostics. The company's offerings in this niche involve innovative products designed to ensure precise and reliable testing for platelet function, which is crucial for the detection of various blood disorders and guiding treatment options. BioRad Laboratories' strengths stem from its solid research and development capabilities as well as its established reputation in the healthcare sector, which bolster confidence among healthcare providers and strengthen customer loyalty.

Its ability to quickly adapt to market needs and maintain high-quality standards enhances its competitive stance in the US market, allowing it to cater effectively to a diverse clientele ranging from hospitals to specialized laboratories.

Terumo Corporation has also carved a niche for itself within the US Platelet Aggregation Devices Market through its commitment to quality and innovation in medical technology. The company offers a range of cutting-edge platelet aggregation testing devices that facilitate accurate assessments, which is essential for monitoring patient responses to antiplatelet therapies. Terumo Corporation's market presence in the US is bolstered by its strong distribution channels and strategic partnerships, which enhance accessibility to its products across various healthcare settings. The strengths of Terumo Corporation revolve around its investment in extensive research initiatives aimed at enhancing product functionality and reliability.

The company is continually expanding its portfolio through mergers and acquisitions to integrate complementary technologies that enhance its existing capabilities, thereby positioning itself favorably within the competitive landscape of the platelet aggregation devices market in the US.

### **Key Companies in the US Platelet Aggregation Devices Market Include**

## **US Platelet Aggregation Devices Market Industry Developments**

The US Platelet Aggregation Devices Market has seen notable developments recently, with significant advancements from key players like BioRad Laboratories, Terumo Corporation, and Abbott Laboratories, focused on enhancing diagnostic capabilities and patient outcomes. Growth in market valuation for companies such as Boston Scientific and Medtronic has impacted competitive dynamics, as they continue to innovate in the realm of cardiovascular diagnostics.

In July 2023, Grifols entered into a collaborative agreement to enhance research on platelet aggregation, further establishing its footprint in this domain. Additionally, in August 2023, Roche announced an expansion of their platelet functionality test offerings, which is anticipated to broaden their market reach. The recent merger between Becton Dickinson and a biotech firm in early June 2023 aimed at consolidating resources for advanced platelet testing supports the trend of industry consolidation.

Furthermore, the market is projected to grow significantly due to increasing cardiovascular diseases within the US, with government initiatives focusing on advanced medical technologies influencing regulatory landscapes and funding opportunities. The ongoing emphasis on Research and Development among these major players highlights the importance of innovation in addressing rising healthcare demands in the platelet aggregation sector.

## **US Platelet Aggregation Devices Market Segmentation Insights**

### **Platelet Aggregation Devices Market Type Outlook**

### **Platelet Aggregation Devices Market Application Outlook**

### **Platelet Aggregation Devices Market End User Outlook**

### **Platelet Aggregation Devices Market Modality Outlook**

## Market Drivers

### Advancements in Point-of-Care Testing

The evolution of point-of-care testing technologies is transforming the landscape of the platelet aggregation-devices market. These innovations facilitate rapid and accurate testing, allowing healthcare professionals to make informed decisions at the bedside. The convenience and efficiency of point-of-care devices are particularly appealing in emergency settings, where timely diagnosis is crucial. As a result, the market for these devices is projected to grow significantly, with estimates suggesting a value of $1.5 billion by 2027. The integration of advanced technologies, such as microfluidics and biosensors, enhances the functionality of platelet aggregation devices, making them indispensable tools in clinical practice. This trend underscores the importance of technological advancements in driving the platelet aggregation-devices market.

### Increasing Prevalence of Cardiovascular Diseases

The rising incidence of cardiovascular diseases in the US is a primary driver for the platelet aggregation-devices market. As heart-related ailments continue to escalate, the demand for effective diagnostic tools becomes critical. According to recent data, cardiovascular diseases account for approximately 697,000 deaths annually in the US, highlighting the urgent need for advanced monitoring and treatment options. This trend is likely to propel the adoption of platelet aggregation devices, as healthcare providers seek to enhance patient outcomes through timely interventions. The platelet aggregation-devices market is expected to witness substantial growth, with projections indicating a compound annual growth rate (CAGR) of around 4.65% over the next few years. Consequently, the increasing prevalence of these diseases is a significant factor driving market expansion.

### Regulatory Support for Innovative Medical Devices

Regulatory bodies in the US are increasingly supportive of innovative medical devices, which is positively impacting the platelet aggregation-devices market. The Food and Drug Administration (FDA) has streamlined the approval process for novel diagnostic tools, encouraging manufacturers to invest in research and development. This regulatory environment fosters innovation, enabling the introduction of advanced platelet aggregation devices that meet the evolving needs of healthcare providers. As a result, the market is likely to experience a surge in new product launches, enhancing competition and driving growth. The platelet aggregation-devices market stands to gain from this supportive regulatory landscape, as it encourages the development of cutting-edge technologies that improve patient care.

### Growing Awareness of Thrombosis and Its Implications

Increased awareness regarding thrombosis and its associated risks is contributing to the growth of the platelet aggregation-devices market. Educational initiatives and campaigns aimed at both healthcare professionals and the general public are fostering a better understanding of the importance of platelet function testing. As individuals become more informed about the potential dangers of thrombosis, there is a corresponding rise in demand for diagnostic tools that can assess platelet aggregation. This heightened awareness is likely to lead to an increase in testing rates, thereby driving market growth. The platelet aggregation-devices market is expected to benefit from this trend, as healthcare providers seek to implement effective screening and monitoring strategies for at-risk populations.

### Rising Geriatric Population and Associated Health Issues

The increasing geriatric population in the US is a significant driver of the platelet aggregation-devices market. As individuals age, they become more susceptible to various health issues, including cardiovascular diseases and thrombotic disorders. This demographic shift necessitates the implementation of effective diagnostic and monitoring tools to manage these conditions. Projections indicate that by 2030, approximately 20% of the US population will be aged 65 and older, further amplifying the demand for platelet aggregation devices. Healthcare providers are likely to prioritize the use of these devices to ensure timely interventions and improve patient outcomes. Consequently, the aging population is a crucial factor influencing the growth trajectory of the platelet aggregation-devices market.

## Future Outlook

The [Platelet Aggregation Devices Market](https://www.marketresearchfuture.com/reports/platelet-aggregation-devices-market-7450) is projected to grow at 4.65% CAGR from 2025 to 2035, driven by technological advancements and increasing cardiovascular disease prevalence.

**New opportunities:**

- Development of portable platelet aggregation testing devices for home use. Integration of AI analytics in platelet aggregation testing for enhanced accuracy. Expansion of distribution channels through telehealth partnerships.

By 2035, the market is expected to achieve substantial growth, driven by innovation and strategic partnerships.

## Segment Insights

### By Type: Optical Aggregation Devices (Largest) vs. Electrochemical Aggregation Devices (Fastest-Growing)

In the US platelet aggregation-devices market, Optical Aggregation Devices hold the largest market share, appealing to healthcare providers due to their reliability and accuracy in diagnosing platelet function. In contrast, Electrochemical Aggregation Devices, while currently smaller in market presence, are rapidly gaining traction among clinicians, thanks to advancements in technology that enhance their precision and usability. Whole Blood Aggregation Devices are also significant, offering unique advantages but faced with increasing competition from the other two types. The growth trends in this segment are fueled by a rising emphasis on personalized medicine and the increasing prevalence of platelet disorders. With technological innovations, Electrochemical Devices are becoming popular for their rapid results, making them attractive for emergency settings. Meanwhile, Optical Devices continue to lead due to their established reputation and widespread adoption. Overall, the market dynamics suggest a competitive landscape with opportunities for growth across all devices.

Technology: Optical Aggregation Devices (Dominant) vs. Electrochemical Aggregation Devices (Emerging)

Optical Aggregation Devices are characterized by their established presence in clinical laboratories, providing precise and reproducible results that healthcare providers rely on for critical assessments of platelet functionality. They dominate the market due to their proven track record and extensive validation in various medical settings. On the other hand, Electrochemical Aggregation Devices are emerging as a newer technology, appealing for their rapid testing capabilities and improved ergonomics, making them suitable for point-of-care applications. These devices are designed to meet the growing demand for efficiency in medical diagnostics, particularly in acute care. The competitive landscape indicates a healthy coexistence of both technologies, each serving unique needs and preferences in platelet aggregometry.

### By Application: Cardiology (Largest) vs. Oncology (Fastest-Growing)

In the US platelet aggregation-devices market, the Application segment reveals a dynamic distribution of market share among key areas, with Cardiology holding the largest share. This is largely due to the increasing prevalence of cardiovascular diseases which has led to heightened demand for effective diagnostic and therapeutic devices. Following closely is the Oncology segment, which, while smaller in comparison to Cardiology, is experiencing rapid growth as advancements in cancer therapies and increased screening programs drive the need for innovative aggregation solutions. Growth trends within the Application segment are shaped by various factors, including an aging population, rising awareness about cardiovascular health, and the development of new technologies in both Cardiology and Oncology. Moreover, Neurology and Vascular Disorders are emerging segments that are gaining traction, as burgeoning research into neurological disorders and advanced interventions for vascular conditions bolster their market presence. This multifaceted landscape indicates a promising future for the US platelet aggregation-devices market, driven by innovation and increased healthcare investments.

Cardiology (Dominant) vs. Oncology (Emerging)

The Cardiology segment is recognized as the dominant force in the US platelet aggregation-devices market, characterized by its extensive usage in cardiovascular diagnostics and [treatment](../../../reports/rosacea-treatment-market-19221) protocols. This segment benefits from a robust infrastructure for heart health management, with numerous specialized devices in use, catering to a diverse patient demographic. In contrast, the Oncology segment is emerging rapidly, propelled by the need for precise diagnostic tools in cancer treatment regimens. While currently trailing behind Cardiology, Oncology is gaining attention due to enhanced focus on personalized medicine and cancer screening initiatives. The convergence of technological advancements in both segments reflects an evolving market that aligns with current healthcare trends and patient needs.

### By End User: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing)

In the US platelet aggregation-devices market, hospitals represent the largest segment, garnering a significant share of the market due to their extensive patient base and need for advanced diagnostic capabilities. Diagnostic laboratories are positioned as a rapidly growing segment, driven by increasing demand for precision medicine and personalized healthcare, making them critical players in the landscape. Growth trends for the US platelet aggregation-devices market highlight the increasing investments in healthcare infrastructure, coupled with a rise in cardiovascular diseases. Research institutions are also contributing to market expansion through innovative research and development. The adoption of point-of-care testing in hospitals further enhances efficiency, whereas diagnostic laboratories are incorporating state-of-the-art technologies to meet the evolving requirements for accurate and timely diagnosis.

Hospitals (Dominant) vs. Research Institutions (Emerging)

Hospitals serve as the dominant players in the US platelet aggregation-devices market, equipped with advanced technologies and a high volume of patient interactions, which facilitate widespread utilization of these devices. Their significant resources allow for continuous upgrades to the latest devices, ensuring optimal patient outcomes. On the other hand, research institutions represent an emerging segment, focusing on innovative applications and conducting pivotal studies that contribute to advancements in platelet aggregation methodologies. While hospitals are primarily driven by immediate clinical needs, research institutions are more focused on long-term developments and novel applications, positioning themselves to play a crucial role in future advancements in the market.

### By Modality: Laboratory Testing (Largest) vs. Point of Care Testing (Fastest-Growing)

The market share distribution within the modality segment reveals that Laboratory Testing holds the largest share due to its established use in hospitals and diagnostic labs. This modality benefits from robust clinical protocols and provider familiarity, leading to widespread adoption across various healthcare settings. Conversely, Point of Care Testing, while smaller in market share, is rapidly gaining traction due to its ability to provide immediate results, enhancing patient management and treatment decisions. Growth trends indicate a significant shift towards Point of Care Testing as it meets the demand for rapid and accurate diagnostics. Factors driving this segment's growth include technological advancements, increasing patient preference for at-home testing, and the need for timely clinical decision-making in emergency care settings. As healthcare systems adapt to changing landscapes, Point of Care Testing is expected to become a critical component in patient care pathways, further driving market dynamics.

Laboratory Testing: Dominant vs. Point of Care Testing: Emerging

Laboratory Testing remains the dominant player in the modality segment, offering comprehensive testing capabilities that ensure accuracy and reliability. Its integration into standard clinical workflows makes it indispensable, particularly for complex diagnostic assessments. On the other hand, Point of Care Testing is emerging as a crucial addition, appealing to healthcare providers seeking efficiency and quicker turnaround times. This modality leverages innovative technologies to deliver results directly at the patient’s side, fostering better clinical outcomes. While Laboratory Testing is preferred for its thoroughness, Point of Care Testing champions convenience and speed, positioning itself as a vital complement to traditional testing methods.

## Competitive Benchmarking

The platelet aggregation-devices market is characterized by a dynamic competitive landscape, driven by technological advancements and increasing demand for precise diagnostic tools. Key players such as Abbott Laboratories (US), Roche Diagnostics (CH), and Thermo Fisher Scientific (US) are at the forefront, each adopting distinct strategies to enhance their market presence. Abbott Laboratories (US) focuses on innovation, particularly in developing next-generation devices that integrate advanced analytics and user-friendly interfaces. Meanwhile, Roche Diagnostics (CH) emphasizes strategic partnerships to expand its product offerings and enhance its technological capabilities. Thermo Fisher Scientific (US) is actively pursuing mergers and acquisitions to bolster its portfolio, indicating a trend towards consolidation in the market. The business tactics employed by these companies reflect a concerted effort to optimize operations and enhance competitiveness. Localizing manufacturing and optimizing supply chains are prevalent strategies aimed at reducing costs and improving responsiveness to market demands. The market structure appears moderately fragmented, with several key players exerting influence while also allowing for niche companies to thrive. This fragmentation fosters innovation, as companies strive to differentiate their offerings in a crowded marketplace. In October 2025, Abbott Laboratories (US) announced the launch of a new platelet aggregation analyzer that utilizes artificial intelligence to enhance diagnostic accuracy. This strategic move is likely to position Abbott as a leader in the market, as AI integration is increasingly viewed as a critical factor in improving patient outcomes. The introduction of this technology not only reflects Abbott's commitment to innovation but also addresses the growing demand for more efficient diagnostic solutions. In September 2025, Roche Diagnostics (CH) entered into a partnership with a leading biotechnology firm to co-develop a novel platelet aggregation testing platform. This collaboration is indicative of Roche's strategy to leverage external expertise and accelerate the development of cutting-edge diagnostic tools. By aligning with innovative partners, Roche aims to enhance its competitive edge and expand its market share in the platelet aggregation segment. In August 2025, Thermo Fisher Scientific (US) completed the acquisition of a smaller diagnostics company specializing in platelet function testing. This acquisition is significant as it not only broadens Thermo Fisher's product range but also strengthens its position in the market by integrating specialized technologies. The move underscores the trend of consolidation within the industry, as larger players seek to enhance their capabilities through strategic acquisitions. As of November 2025, the competitive trends in the platelet aggregation-devices market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation and expanding their reach. Looking ahead, it is anticipated that competitive differentiation will increasingly pivot from price-based strategies to a focus on technological innovation, reliability in supply chains, and the ability to deliver superior patient outcomes. This shift suggests a transformative phase in the market, where companies that prioritize innovation and strategic partnerships are likely to emerge as leaders.

## Recent News & Developments

The US Platelet Aggregation Devices Market has seen notable developments recently, with significant advancements from key players like BioRad Laboratories, Terumo Corporation, and Abbott Laboratories, focused on enhancing diagnostic capabilities and patient outcomes. Growth in market valuation for companies such as Boston Scientific and Medtronic has impacted competitive dynamics, as they continue to innovate in the realm of cardiovascular diagnostics.

In July 2023, Grifols entered into a collaborative agreement to enhance research on platelet aggregation, further establishing its footprint in this domain. Additionally, in August 2023, Roche announced an expansion of their platelet functionality test offerings, which is anticipated to broaden their market reach. The recent merger between Becton Dickinson and a biotech firm in early June 2023 aimed at consolidating resources for advanced platelet testing supports the trend of industry consolidation.

Furthermore, the market is projected to grow significantly due to increasing cardiovascular diseases within the US, with government initiatives focusing on advanced medical technologies influencing regulatory landscapes and funding opportunities. The ongoing emphasis on Research and Development among these major players highlights the importance of innovation in addressing rising healthcare demands in the platelet aggregation sector.

## Report Scope

| MARKET SIZE 2024 | 178.9(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 187.22(USD Million) |
| MARKET SIZE 2035 | 294.99(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.65% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Roche Diagnostics (CH), Siemens Healthineers (DE), Abbott Laboratories (US), Thermo Fisher Scientific (US), Beckman Coulter (US), Sysmex Corporation (JP), Acelity (US), Grifols (ES), HemoSonics (US) |
| Segments Covered | Type, Application, End User, Modality |
| Key Market Opportunities | Advancements in point-of-care testing technologies enhance accessibility in the platelet aggregation-devices market. |
| Key Market Dynamics | Technological advancements and regulatory changes drive innovation in the platelet aggregation-devices market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the overall market valuation of the US platelet aggregation-devices market in 2024?**
A: The overall market valuation was $178.9 Million in 2024.

**Q: What is the projected market valuation for the US platelet aggregation-devices market by 2035?**
A: The projected valuation for 2035 is $294.99 Million.

**Q: What is the expected CAGR for the US platelet aggregation-devices market during the forecast period 2025 - 2035?**
A: The expected CAGR during the forecast period 2025 - 2035 is 4.65%.

**Q: Which segment had the highest valuation in the US platelet aggregation-devices market in 2024?**
A: The Whole Blood Aggregation Devices segment had the highest valuation at $134.99 Million.

**Q: What are the key applications of platelet aggregation-devices in the US market?**
A: Key applications include Cardiology, Oncology, Neurology, and Vascular Disorders.

**Q: Which end user segment contributed the most to the US platelet aggregation-devices market in 2024?**
A: Hospitals contributed the most, with a valuation of $110.0 Million.

**Q: What is the valuation range for Optical Aggregation Devices in the US market?**
A: The valuation range for Optical Aggregation Devices is $40.0 Million to $65.0 Million.

**Q: How does the valuation of Laboratory Testing compare to Point of Care Testing in the US market?**
A: Laboratory Testing has a higher valuation range of $107.34 Million to $179.99 Million compared to Point of Care Testing, which ranges from $71.56 Million to $115.0 Million.

**Q: Who are the key players in the US platelet aggregation-devices market?**
A: Key players include Roche Diagnostics, Siemens Healthineers, Abbott Laboratories, and Thermo Fisher Scientific.

**Q: What is the projected growth trend for the US platelet aggregation-devices market from 2025 to 2035?**
A: The market is expected to grow steadily, reaching $294.99 Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-platelet-aggregation-devices-market-17628*